Ramy Mohammed Rashad, MD
Ophthalmology · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Southern California Permanente Medical Group · 11,250 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Rashad’s office to ask if they take your plan before you enroll.
Original Medicare doctor bills
$3,593
Medicare paid this office $3,593 for 34 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 18 | $1,069 | $59 |
Who their Medicare patients are
34 Original Medicare patients in 2024. Average age 74 · Women 62% · Also on Medicaid 32% · Health risk score 1.80. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 38%.
The office billed $52,956, Medicare allowed $4,510 and paid $3,593; for 41 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Drugs they prescribed that Part D paid
$110,329
Pharmacies billed $110,329 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,007) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
656 generic and 351 brand-name prescriptions · $110,329 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Restasis | 13 | $8,313 | $639 |
| Cyclosporine | 20 | $7,644 | $382 |
| Rhopressa | 18 | $6,468 | $359 |
| Prednisolone Acetate | 113 | $5,100 | $45 |
| Brimonidine | 132 | $4,109 | $31 |
See all 14 drugs
| Restasis | 13 | $8,313 | $639 |
| Cyclosporine | 20 | $7,644 | $382 |
| Rhopressa | 18 | $6,468 | $359 |
| Prednisolone Acetate | 113 | $5,100 | $45 |
| Brimonidine | 132 | $4,109 | $31 |
| Latanoprost | 271 | $2,966 | $11 |
| Dorzolamide-Timolol | 100 | $1,775 | $18 |
| Fluorometholone | 17 | $1,254 | $74 |
| Moxifloxacin | 28 | $945 | $34 |
| Dorzolamide | 30 | $717 | $24 |
| Ofloxacin | 49 | $712 | $15 |
| Timolol Maleate | 51 | $667 | $13 |
| Ketorolac Tromethamine | 25 | $507 | $20 |
| Erythromycin | 24 | $272 | $11 |
Year by year
| 2024 | 1,007 | 332 | 0% (0) | 35% | $110,329 |
| 2023 | 851 | 290 | 0% (0) | 26% | $48,219 |
| 2022 | 1,281 | 327 | None | 29% | $113,502 |
| 2021 | 516 | 190 | None | None | $44,345 |
| 2020 | 44 | 14 | 0% (0) | None | $992 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Rhopressa | 22 | $7,700 | $350 |
| Alphagan P | 17 | $7,349 | $432 |
| Prednisolone Acetate | 94 | $3,667 | $39 |
| Latanoprost | 209 | $3,249 | $16 |
| Brimonidine | 128 | $3,051 | $24 |
| Dorzolamide-Timolol | 98 | $2,863 | $29 |
| Ketorolac Tromethamine | 71 | $1,460 | $21 |
| Ofloxacin | 72 | $1,116 | $16 |
| Dorzolamide | 36 | $971 | $27 |
| Timolol Maleate | 36 | $620 | $17 |
2022: 12 drugs
| Rhopressa | 64 | $28,670 | $448 |
| Alphagan P | 34 | $17,189 | $506 |
| Brimonidine | 252 | $10,997 | $44 |
| Lumigan | 21 | $10,719 | $510 |
| Methazolamide | 20 | $8,495 | $425 |
| Latanoprost | 427 | $7,013 | $16 |
| Dorzolamide-Timolol | 161 | $4,653 | $29 |
| Dorzolamide | 81 | $2,632 | $32 |
| Travoprost | 14 | $2,397 | $171 |
| Timolol Maleate | 74 | $1,632 | $22 |
| Prednisolone Acetate | 24 | $1,596 | $66 |
| Erythromycin | 21 | $282 | $13 |
2021: 8 drugs
| Alphagan P | 23 | $9,493 | $413 |
| Brimonidine | 68 | $3,595 | $53 |
| Latanoprost | 135 | $1,994 | $15 |
| Dorzolamide-Timolol | 54 | $1,796 | $33 |
| Prednisolone Acetate | 17 | $867 | $51 |
| Dorzolamide | 34 | $787 | $23 |
| Timolol Maleate | 24 | $719 | $30 |
| Atorvastatin | 11 | $420 | $38 |
Money from drug and device companies
$23 in 2025
| 2025 | 1 | 1 | None | $23 |
| 2024 | 2 | 2 | None | $251 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| RxSight | Rxsight Contact Lens | $23 | 1 payment
|
See the published payment
| RxSight | Meals · 2025-04-18 | Rxsight Contact Lens | $23 |
See earlier years (2024)
2024: $251
| Sight Sciences | Omni Surgical System | $144 | 1 payment
|
| Abbvie | Ozurdex | $107 | 1 payment
|
Professional record
- NPI
- 1982233045
- Trained
- Tufts University School of Medicine, 2020
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Student in a training program (390200000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2020-04-02
- NPI last updated
- 2024-10-08
- NPI record certified
- 2024-10-08
This is when the NPI record was last certified, not a medical board exam.